tiragolumab + atezolizumab

Tiragolumab + atezolizumab is a combination of two monoclonal antibody immunotherapies developed for the treatment of various cancers, particularly advanced solid tumors and non-small cell lung cancer (NSCLC). Tiragolumab is an anti-TIGIT monoclonal antibody that blocks the T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells, preventing its interaction with the poliovirus receptor (PVR/CD155), thereby amplifying immune responses against tumor cells. Atezolizumab (marketed as Tecentriq) is an anti-PD-L1 monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1)-mediated suppression of T-cell activity. The combination aims to enhance antitumor immunity by simultaneously blocking both TIGIT and PD-L1 pathways, potentially leading to improved clinical outcomes compared to monotherapy. This dual blockade has shown encouraging efficacy and safety in clinical trials for patients with PD-L1-positive metastatic NSCLC and other advanced solid tumors[5][7][8].

Brand names

Tecentriq

Other names

tiragolumab + Tecentriq